According to Robotics & Automation News, the global nanorobotics market is forecast to reach $31.44 billion by 2034, expanding from an estimated $9 billion in 2025 at a compound annual growth rate of 14.9 percent.
Primary Growth Drivers
Targeted drug delivery remains the largest commercial application for nanorobotics, with research increasingly focused on delivering therapeutics directly to diseased cells while minimizing off-target effects on healthy tissue. This precision capability underpins demand across oncology, regenerative medicine, and diagnostics.
The market expansion reflects accelerating translational progress: Polaris Market Research, cited in the report, attributes growth to validated preclinical outcomes and rising investment in clinical pathway development. The firm’s analysis covers regional adoption patterns, material innovations, and regulatory engagement timelines across North America, Europe, and Asia-Pacific.
Preclinical Validation Milestones
Researchers at Sweden’s Karolinska Institute have developed a DNA-based nanorobot that activates specifically within the tumor microenvironment, achieving a 70 percent reduction in tumor growth in preclinical models. Similarly, scientists at the Institute for Bioengineering of Catalonia (IBEC) demonstrated autonomous therapeutic nanorobots that reduced bladder tumors by up to 90 percent in controlled studies.
These results reinforce the technology’s therapeutic specificity and support ongoing efforts to scale manufacturing processes and meet Good Manufacturing Practice (GMP) standards. The studies were conducted between 2025 and 2026, with peer-reviewed publications released as of August 21, 2026.
Source: Robotics & Automation News
Compiled from international media by the SCI.AI editorial team.
